Investors purchased shares of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) on weakness during trading on Wednesday. $11.32 million flowed into the stock on the tick-up and $8.74 million flowed out of the stock on the tick-down, for a money net flow of $2.58 million into the stock. Of all stocks tracked, Intra-Cellular Therapies had the 28th highest net in-flow for the day. Intra-Cellular Therapies traded down ($2.70) for the day and closed at $40.89

A number of research analysts have recently issued reports on the stock. Leerink Swann restated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Thursday, June 30th. Cowen and Company restated a “buy” rating on shares of Intra-Cellular Therapies in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a research report on Wednesday, June 29th. Finally, Piper Jaffray Cos. restated an “overweight” rating and issued a $57.00 price target on shares of Intra-Cellular Therapies in a research report on Tuesday, September 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Intra-Cellular Therapies presently has an average rating of “Buy” and a consensus target price of $70.25.

The stock’s 50-day moving average price is $41.78 and its 200-day moving average price is $36.94. The company’s market cap is $1.77 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/traders-buy-shares-of-intra-cellular-therapies-inc-itci-on-weakness.html

Intra-Cellular Therapies (NASDAQ:ITCI) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. The company earned $0.23 million during the quarter, compared to the consensus estimate of $0.02 million. The firm’s revenue for the quarter was up 283.3% on a year-over-year basis. During the same quarter last year, the company posted ($0.61) earnings per share. Analysts expect that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Intra-Cellular Therapies by 49.6% in the second quarter. Vanguard Group Inc. now owns 2,355,713 shares of the biopharmaceutical company’s stock worth $91,449,000 after buying an additional 781,550 shares during the last quarter. TimesSquare Capital Management LLC boosted its position in shares of Intra-Cellular Therapies by 6.3% in the second quarter. TimesSquare Capital Management LLC now owns 1,619,875 shares of the biopharmaceutical company’s stock worth $62,884,000 after buying an additional 95,500 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its position in shares of Intra-Cellular Therapies by 2.2% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,100,000 shares of the biopharmaceutical company’s stock worth $30,580,000 after buying an additional 23,538 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Intra-Cellular Therapies by 7.4% in the second quarter. BlackRock Fund Advisors now owns 1,043,100 shares of the biopharmaceutical company’s stock worth $40,493,000 after buying an additional 72,160 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Intra-Cellular Therapies by 9.3% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 788,743 shares of the biopharmaceutical company’s stock worth $30,619,000 after buying an additional 67,349 shares during the last quarter. Institutional investors own 70.15% of the company’s stock.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

5 Day Chart for NASDAQ:ITCI

Receive News & Ratings for Intra-Cellular Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.